Individual patient number | Cancer stage prior to treatment | 1 year | 1.5 year | 2 years | 3 years | |
---|---|---|---|---|---|---|
TNM | AJCC | |||||
Panagen group | ||||||
02-01 | T4NxM0 | IIIB | ND1 | Alive | Alive | Progression. Metastases in lungs |
02-02 | T2N0M0 | IIA | Remission | Remission | Remission | ND |
02-03 | T1N1M0 | IIA | Remission | Remission | Remission | Progression. Metastases in Th11 |
02-04 | T3N2M1 | IV | Deceased. Cause: breast cancer | - | - | - |
02-05 | T4N1M0 | IIIB | Remission | Remission | Remission | ND |
02-06 | T4NxM1 | IV | Deceased. Cause: breast cancer | - | - | - |
02-08 | T4N1M0 | IIIB | Remission | Remission | Remission | ND |
02-09 | T1N1M0 | IIA | Progression. Bone metastases (detected after 1st chemotherapy) | Alive | Alive | ND |
02-10 | T1N1M0 | IIA | Remission | Remission | Remission | Remission |
02-11* | T2N1M0 | IIB | Remission | Remission | Remission | Remission |
02-14 | T2N2M0dex T4N1M0sin | IIIB | Remission | Remission | Remission | Remission |
02-15 | T3N2M0 | IIIA | Remission | Remission | Remission | Remission |
02-16* | T4NxM0 | IIIB | Remission | Cancer relapse. Skin metastases around scar tissue | Partial regression | ND |
02-18* | T4NxM0 | IIIB | ND | Alive | Alive | ND |
02-20 | T2N1M0 | IIB | Remission | Remission | Remission | |
02-21 | T2N0M0 | IIA | Remission | Remission | Remission | |
02-22* | T2N1M0 | IIB | Remission | Remission | Remission | |
02-24 | T2N1M0 | IIB | Remission | Remission | Remission | |
02-25* | T2N2M0 | IIIA | Remission | Remission | Remission | |
02-26 | T1N1M0 | IIA | Remission | Remission | Remission | |
02-27 | T1N2M0 | IIIA | Remission | Remission | ND | |
02-28* | T2N1M0 | IIB | Remission | Remission | ND | |
02-29 | T2N0M0 | IIA | Remission | Remission | ND | |
02-30 | T2NxM0 | II | Remission | Remission | Remission | |
02-31 | T2N1M0 | IIB | Progression. Metastases in lungs | Alive | Alive | |
02-33* | T2N3M0 | IIIC | Remission | ND | ND | |
02-36 | T4NxM0dex T2NxM0sin | IIIB | Treatment is on-going due to chemotherapy scheduling issues | Treatment in progress | ND | |
02-39 | T2N3M0 | IIIC | Remission | Remission | Remission | |
02-40* | T2N1M0 | IIB | Remission | ND | ND | |
02-42* | T1N3M0 | IIIC | Remission | Remission | Remission | |
02-43 | T3N0M0 | IIB | Remission | Remission | Remission | |
02-44* | T1N1M0 | IIA | Progression. Bone metastases (detected after 2nd chemotherapy) | ND | ND | |
02-45* | T4N1M0 | IIIB | Remission | Remission | Remission | |
Final outcome | Progression or death in 8 out of 33 patients (24%) | |||||
Placebo group | ||||||
02-07 | T4N2M0 | IIIB | Deceased. Cause: breast cancer | - | - | - |
02-12* | T2N2M0 | IIIA | Remission | Remission | Remission | ND |
02-13 | T4N3M0 | IIIC | Treatment in progress | Progression. Metastases in lungs | ND | ND |
02-17 | T2N1M0 | IIB | Remission | Remission | Remission | Remission |
02-23* | T2N1M0 | IIB | Progression. Bone metastases | Alive | ND | |
02-32 | T4NxM0 | IIIB | ND | ND | ND | |
02-34 | T4N2M0 | IIIB | ND | ND | ND | |
02-35* | T4NxM0 | IIIB | Remission | Remission | Progression. Metastases in brain | |
02-37* | T4N0M0 | IIIB | Progression. Metastases in brain, lungs, liver and bones | ND | ND | |
02-38 | T2N2M0 | IIIA | ND | ND | ND | |
02-41 | T1N1M0 | IIA | Remission | Remission | Remission | |
Final outcome | Progression or death in 5 out of 11 patients (45%) |